home / stock / capr / capr news

CAPR News and Press, Capricor Therapeutics Inc. From 10/21/19

Stock Information
Company Name: Capricor Therapeutics Inc.
Stock Symbol: CAPR
Market: NASDAQ
Website: capricor.com
Menu
CAPR CAPR Quote CAPR Short CAPR News CAPR Articles CAPR Message Board
Get CAPR Alerts

News, Short Squeeze, Breakout and More Instantly...
CAPR - Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

Call Scheduled for Thursday, October 24 th at 10:30am Eastern Time LOS ANGELES, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (Nasdaq: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duche...
CAPR - Capricor Therapeutics (CAPR) Presents Interim Results from HOPE-2 Trial for CAP-1002 - Slideshow

The following slide deck was published by Capricor Therapeutics, Inc. in conjunction with this Read more ...

CAPR - Healthcare dominate midday movers

Gainers:  Akcea Therapeutics (NASDAQ: AKCA ) +29% . Liquid Media Group (NASDAQ: YVR ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +20% . Sutro Biopharma (NASDAQ: STRO ) +19% . Livongo Health (NASDAQ: LVGO ) +15% . Motus GI Holdings (NASDAQ: MOTS ) +12% . Teekay Tankers (NYSE: TNK )...

CAPR - XENT, CAPR among premarket losers

Intersect ENT XENT  -16%  on failed study of drug-coated sinus balloon. More news on: Capricor Therapeutics, Inc., Stocks on the move, , Read more ...

CAPR - Capricor up 15% premarket on new CAP-1002 data in DMD

Nano cap Capricor Therapeutics (NASDAQ: CAPR ) is up  15%  premarket on modest volume in reaction to additional six-month data on Duchenne muscular dystrophy (DMD) candidate CAP-1002 from the ongoing Phase 2 HOPE-2 study. The results were presented at the World Muscle Society C...

CAPR - Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies-- --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET-- LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ...

CAPR - Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET

LOS ANGELES, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced tha...
CAPR - Key events next week - healthcare

Noteworthy events during the week of September 29 - October 5 for healthcare investors. More news on: Capricor Therapeutics, Inc., Enanta Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Healthcare stocks news, , Read more ...

CAPR - Capricor Therapeutics to review CAP-1002 data with FDA

Capricor Therapeutics (NASDAQ: CAPR ) has been granted a Type B End-of-Phase 2 meeting with the FDA to discuss the prespecified interim analysis of its HOPE 2 trial that evaluated CAP-1002 in steroid-treated boys and young men with Duchenne muscular dystrophy (DMD). More news on: Ca...

CAPR - Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, announced to...
Previous 10 Next 10